First-in-class KAT6A/KAT6B inhibitor CTx-648 (PF-9363) demonstrates potent anti-tumor activity in ER plus breast cancer with KAT6A dysregulation.
Sharma, S; Chung, J; Uryu, S; Rickard, A; Nady, N; Khan, S; Wang, ZX; Zhang, Y; Zhang, HK; Kung, PP; Greenwald, E; Maegley, K; Bingham, P; Lam, H; Bozikis, YE; Falk, H; Allan, E; Avery, VM; Butler, MS; Camerino, MA; Carrasco-Pozo, C; Charman, SA; Davis, MJ; Dawson, MA; Sarah-Jane, D; de Silva, M; Dennis, ML; Dolezal, O; Lagiakos, R; Lindeman, GJ; MacPherson, L; Nuttall, S; Peat, TS; Ren, B; Stupple, AE; Surgenor, E; Tan, CW; Thomas, T; Visvader, JE; Voss, AK; Vaillant, F; White, KL; Whittle, J; Yang, YQ; Hediyeh-Zadeh, S; Stupple, PA; Street, IP; Monahan, BJ; Paul, T
CANCER RESEARCH, 2021; 81 (13):
